EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Clinical features and treatment challenges of HER2-positive primary breast squamous cell carcinoma: a case report and literature review

Fang Yang, Siyu Guo, Ping Li, Mengqi Yang, Xuan Wu

Frontiers in Oncology · 09.07.2026 · 16

DOI: 10.3389/fonc.2026.1781401 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Frontiers in Oncology, online erschienen am 09.07.2026. Verfasst von Fang Yang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Peking University Shenzhen Hospital, Shenzhen, China. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sanming Project of Medicine in Shenzen Municipality, National Natural Science Foundation of China, Science, Technology and Innovation Commission of Shenzhen Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Primary breast squamous cell carcinoma (PBSCC) with HER2-positive status is exceptionally rare, with fewer than 100 cases reported globally, and HER2 positivity occurring in only 5.8-7.1% of these cases. No established treatment standards exist for this entity. We present the case of a 43-year-old woman with HER2-positive PBSCC who exhibited a poor response to neoadjuvant TCHP therapy (Miller-Payne grade 2). Local recurrence occurred just 3 months after mastectomy. Second-line therapy with pyrotinib plus capecitabine provided 9 months of disease control before lung metastasis emerged. Subsequent molecular profiling revealed a PIK3CA E545K mutation (VAF 40.3%), co-amplified with FGF3/4/19 and CCND1 . Although third-line treatment with trastuzumab deruxtecan (T-DXd) achieved a partial response, the progression-free survival (PFS) was limited to only 5 months. A repeat biopsy confirmed HER2 downregulation (from 3+ to 2+), identifying antigen loss as a key mechanism of acquired resistance. A review of the literature indicates that the pathological complete response rate of HER2-positive PBSCC to standard HER2-targeted therapy is remarkably low, far inferior to the 50-60% pCR rates achieved with dual HER2 blockade in HER2-positive invasive ductal carcinoma. This case underscores that upon failure of HER2-targeted therapy accompanied by HER2 antigen loss, the treatment strategy should pivot towards molecularly-guided precision therapy. Based on evidence such as that from the TRIUMPH trial, priority should be given to agents targeting the detected alterations, such as PIK3CA or FGFR inhibitors, rather than persisting with HER2-targeted approaches.

Schlagwörter

Stichwörter der Autor:innen

HER2 amplificationPIK3CA mutationantigen lossbreast squamous cell carcinomaprecision therapy

Autor:innen und Institutionen

  • Department of Oncology, Peking University Shenzhen Hospital, Shenzhen, China.
  • Department of Radiotherapy, Peking University Shenzhen Hospital, The First School of Clinical Medicine, Guangdong Medical University, Shenzhen, China.
  • Department of Pathology, Peking University Shenzhen Hospital, Shenzhen, China.
  • Department of Radiotherapy, Peking University Shenzhen Hospital, Shenzhen, China.
  • Department of Oncology, Peking University Shenzhen Hospital, The First School of Clinical Medicine, Guangdong Medical University, Shenzhen, China.

Förderung

  • Sanming Project of Medicine in Shenzen Municipality
  • National Natural Science Foundation of China
  • Science, Technology and Innovation Commission of Shenzhen Municipality

Zitieren

APA

Yang, F., Guo, S., Li, P., Yang, M., & Wu, X. (2026). Clinical features and treatment challenges of HER2-positive primary breast squamous cell carcinoma: a case report and literature review. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1781401

Vancouver

Yang F, Guo S, Li P, Yang M, Wu X. Clinical features and treatment challenges of HER2-positive primary breast squamous cell carcinoma: a case report and literature review. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1781401

BibTeX
@article{Yang2026,
  author = {Yang, Fang and Guo, Siyu and Li, Ping and Yang, Mengqi and Wu, Xuan},
  title = {Clinical features and treatment challenges of HER2-positive primary breast squamous cell carcinoma: a case report and literature review},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1781401}
}
Kostenlos starten →